News
December 11, 2025
IR
Supplementary Materials of Consolidated Financial Results for the Three Months Ended October 31 2025 
December 11, 2025
IR
[Summary]Consolidated Financial Results for the Three Months Ended October 31, 2025 (Under Japanese GAAP)
November 17, 2025
IR
Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation
November 13, 2025
R&D
Pharma Foods Partners with The University of Tokyo For Next-Generation Antibody Drug Discovery ～A Leap Forward with AI and Advanced Molecular Engineering～
September 30, 2025
IR
Notice of the 28th Annual General Meeting of Shareholders
September 25, 2025
IR
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)
September 24, 2025
R&D
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
September 19, 2025
IR
Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal
September 19, 2025
IR
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
IR
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)
December 11, 2025
IR
[Summary]Consolidated Financial Results for the Three Months Ended October 31, 2025 (Under Japanese GAAP)
November 17, 2025
IR
Notice Regarding the Disposal of Treasury Shares as Restricted Stock Compensation
November 13, 2025
R&D
Pharma Foods Partners with The University of Tokyo For Next-Generation Antibody Drug Discovery ～A Leap Forward with AI and Advanced Molecular Engineering～
September 30, 2025
IR
Notice of the 28th Annual General Meeting of Shareholders
September 25, 2025
IR
Consolidated Financial Results for the Year Ended July 31, 2025 (Based on Japanese GAAP)
September 24, 2025
R&D
“ALAgene® technology”-Derived Antibody Therapeutic Candidate Achieves Phase I Clinical Milestone ～Driving Future Growth through Strategic License Agreement～
September 19, 2025
IR
Notice Regarding the Board of Directors’ Opinion on a Shareholder Proposal
September 19, 2025
IR
Notice Regarding Partial Amendments to the Articles of Incorporation
September 11, 2025
IR
[Summary] Consolidated Financial Results for the Fiscal Year Ended July 31, 2025 (Under Japanese GAAP)